Blog
RSS FeedPosted by Michael Wonder on 15 Nov 2019
Meningitis Foundation calls for PHARMAC to protect everyone
15 November 2019 - Following PHARMAC’s announcement stating the meningococcal ACWY vaccine will be available free from next month for ...
Posted by Michael Wonder on 14 Nov 2019
PHARMAC widening access to the meningococcal ACWY vaccine
14 November 2019 - The meningococcal ACWY vaccine will be available free from next month for young people in close ...
Posted by Michael Wonder on 12 Nov 2019
Merck’s Ervebo [Ebola Zaire vaccine (rVSVΔG-ZEBOV-GP) live] granted conditional approval in the European Union
12 November 2019 - Authorisation represents significant advancement in the global response to Ebola. ...
Posted by Michael Wonder on 09 Nov 2019
Johnson & Johnson announces submission of European marketing authorisation applications for Janssen’s investigational Ebola vaccine regimen
7 November 2019 - Data from multiple preclinical, Phase 1, 2 and 3 studies support applications, which have been granted Accelerated ...
Posted by Michael Wonder on 05 Nov 2019
FDA approves Fluzone High-Dose quadrivalent (influenza vaccine) for adults 65 years of age and older
4 November 2019 - Will be available in fall 2020, in time for the 2020-2021 flu season. ...
Posted by Michael Wonder on 01 Nov 2019
Report clearly demonstrates the value of vaccines
1 November 2019 - Medicines Australia welcomes today’s report from the Australian Institute of Health and Welfare which verifies the ...
Posted by Michael Wonder on 31 Oct 2019
New Zealand Pharmaceutical Schedule - 1 November 2019
1 November 2019 - The November 2019 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 24 Oct 2019
Benefit payments for Australian father cut while son receives cancer treatment
24 October 2019 - A Perth father has reportedly lost his Family Tax Benefit cut because his son wasn't vaccinated. ...
Posted by Michael Wonder on 19 Oct 2019
Merck receives EU CHMP positive opinion for investigational V920 Ebola Zaire vaccine for protection against Ebola virus disease
18 October 2019 - Merck today announced that the CHMP of the EMA has adopted a positive opinion recommending a conditional ...
Posted by Michael Wonder on 17 Oct 2019
Complexity in assessing the benefit versus risk of vaccines: experience with rotavirus and dengue virus vaccines
17 October 2019 - The remarkable contribution of immunisation programs to public health is recognised by most people, including those who ...
Posted by Michael Wonder on 16 Oct 2019
First Algenex CrisBio-based vaccine submitted to European Medicines Agency
15 October 2019 - Potential approval would validate the use of Algenex’ CrisBio technology for the manufacture of recombinant subunit vaccines. ...
Posted by Michael Wonder on 10 Oct 2019
Emergent BioSolutions receives EMA Prime Designation for its Chikungunya virus vaccine candidate
10 October 2019 - Emergent BioSolutions today announced that the company’s chikungunya virus (CHIKV) virus-like particle (VLP) vaccine candidate, CHIKV VLP, ...
Posted by Michael Wonder on 25 Sep 2019
FDA approves first live, non-replicating vaccine to prevent smallpox and monkeypox
24 September 2019 - The U.S. FDA announced today the approval of Jynneos Smallpox and Monkeypox Vaccine, Live, Non-Replicating, for the ...
Posted by Michael Wonder on 17 Sep 2019
FDA accepts Merck’s biologics license application and grants priority review for V920, the company’s investigational vaccine for Ebola Zaire virus
17 September 2019 - Merck continues to expand investigational supply to support international Ebola outbreak response. ...
Posted by Michael Wonder on 17 Sep 2019
PHARMAC may have to compete for measles vaccine
17 September 2019 - PHARMAC is looking at whether it can order more measles vaccine in case the latest batch runs ...